S. Couture, Liktor-Busa, Villar Martinez, Gongora-Rivera, Hernandez-Sanchez, Pte. Cons, Mexico Col. Obispado, Razeghi Jahromi
{"title":"American Headache Society 66th Annual Scientific Meeting June 13–16, 2024 San Diego, California","authors":"S. Couture, Liktor-Busa, Villar Martinez, Gongora-Rivera, Hernandez-Sanchez, Pte. Cons, Mexico Col. Obispado, Razeghi Jahromi","doi":"10.1111/head.14771","DOIUrl":null,"url":null,"abstract":"ABHD6 partially reversed medication overuse headache induced allodynia induced by sumatriptan. Background : The pathophysiology of headache disorders such as medication overuse headache (MOH) is poorly understood, making treatment difficult. However, recent evidence has implicated the involvement of endocannabinoid deficiency, specifically in decreased levels of 2-AG within periaqueductal gray (PAG), in multiple models of headache pain. Our previous research has shown that blockade of 2-AG degradation using a selective ABHD6 inhibitor, KT-182, both prevented and reversed periorbital allodynia in a cortical spreading depression (CSD) headache model. Given our observations that MOH also reduced PAG levels of 2-AG, this study aimed to evaluate the efficacy of inhibiting ABHD6 for MOH headache like pain behaviors","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"79 5‐6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Headache: The Journal of Head and Face Pain","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/head.14771","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
ABHD6 partially reversed medication overuse headache induced allodynia induced by sumatriptan. Background : The pathophysiology of headache disorders such as medication overuse headache (MOH) is poorly understood, making treatment difficult. However, recent evidence has implicated the involvement of endocannabinoid deficiency, specifically in decreased levels of 2-AG within periaqueductal gray (PAG), in multiple models of headache pain. Our previous research has shown that blockade of 2-AG degradation using a selective ABHD6 inhibitor, KT-182, both prevented and reversed periorbital allodynia in a cortical spreading depression (CSD) headache model. Given our observations that MOH also reduced PAG levels of 2-AG, this study aimed to evaluate the efficacy of inhibiting ABHD6 for MOH headache like pain behaviors
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
